Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05060432 · ClinicalTrials.gov registry record · Phase 1

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

A Phase 1 study of Lung Cancer and Melanoma, sponsored by iTeos Belgium.

Active
Registry status
Phase 1
Development phase
153
Enrollment target
20
Study locations

NCT05060432 is a Phase 1 study of Lung Cancer and Melanoma that is active but no longer recruiting, run by iTeos Belgium. The registered enrollment target is 153 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05060432, a Phase 1 study of Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by iTeos Belgium.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
153 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.

Conditions Studied

Lung Cancer Melanoma Head and Neck Cancer Advanced Cancer

Interventions

  • DRUG pembrolizumab
  • DRUG Dostarlimab
  • DRUG inupadenant
  • DRUG EOS-448
  • DRUG SOC chemotherapies

Study Locations (20)

Other

  • Cliniques universitaires St Luc-UCL - Brussels
  • Jessa Ziekenhuis - Hasselt
  • UZ Leuven - Leuven
  • CHU Helora - Mons
  • Hôpital Saint André - Bordeaux
  • CHU Caen - Caen
  • Centre Georges Francois Leclerc - Dijon
  • Clinique Victor Hugo - Le Mans
  • Centre Oscar Lambret - Lille
  • Centre Léon Bérard - Lyon
  • Institut de Cancerologie Lorraine (ICL) - Nancy
  • Institut de Cancérologie de l'Ouest - Nantes
  • Centre Antoine Lacassagne - Nice
  • Pitié Salpêtrière - Paris
  • CHU de POITIERS - Poitiers
  • ICANS - Strasbourg

California

  • University of California San Diego - San Diego

New Jersey

  • Hackensack University Medical Center - Bergen

Antwerp

  • GZA Ziekenhuizen campus Sint-Augustinus - Antwerp

Milan

  • IDB Center-Istituto Clinico Humanitas (IRCCS) - Rozzano

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2021-09-06
Est. Completion 2025-07
Phase Phase 1

Sponsor

iTeos Belgium

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05060432

The ClinicalTrials.gov registry entry for NCT05060432 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is iTeos Belgium, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.

NCT05060432 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, California, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05060432 about?

NCT05060432 is a clinical study titled "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors". This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants ...

What is the current status of trial NCT05060432?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2021-09-06. Estimated completion is 2025-07.

What conditions does trial NCT05060432 study?

This clinical trial studies the following conditions: Lung Cancer, Melanoma, Head and Neck Cancer, Advanced Cancer.

What interventions are being tested in trial NCT05060432?

The interventions under investigation include: pembrolizumab (DRUG), Dostarlimab (DRUG), inupadenant (DRUG), EOS-448 (DRUG), SOC chemotherapies (DRUG).

Who is sponsoring clinical trial NCT05060432?

This trial is sponsored by iTeos Belgium, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05060432 being conducted?

This trial has 20 study locations across California, New Jersey, Antwerp, Milan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.